Mesalazin Orion

Mesalazine, the active ingredient in Mesalazin Orion, is a 5‑aminosalicylic acid (5‑ASA) derivative presented as an oral formulation for oral use. It is employed to treat inflammatory bowel disease, specifically ulcerative colitis and Crohn’s disease with colonic involvement, in adult patients.

GNH USA supplies Mesalazin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazin Orion is a 5‑ASA drug used in the management of inflammatory bowel disorders.

- Ulcerative colitis: reduces colonic inflammation and helps maintain remission in patients with active disease. - Crohn's disease (colonic involvement): controls inflammation in the colon and supports symptom relief during flare‑ups.

Mesalazin Orion may cause adverse reactions ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Abdominal pain: cramping or discomfort. - Flatulence: increased intestinal gas. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reaction: hives, swelling, or anaphylaxis. - Blood dyscrasias: neutropenia or agranulocytosis. - Liver enzyme elevation: signs of hepatic injury. - Nephrotoxicity: impaired kidney function.

Before prescribing Mesalazin Orion, clinicians should consider several safety measures.

- Renal function monitoring: assess kidney status regularly. - Hepatic assessment: check liver enzymes prior to initiation. - Hypersensitivity screening: avoid in patients with known allergy to mesalazine or related compounds. - NSAID caution: concurrent use may increase gastrointestinal irritation. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mesalazin Orion can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Azathioprine: increased risk of bone‑marrow suppression. - Warfarin: potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Sulfasalazine: additive gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy. - Allopurinol: may raise mesalazine plasma concentrations.